Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy
Biol. Res
;
47: 1-9, 2014. ilus, graf
Article
Dans Anglais
| LILACS
| ID: biblio-950723
ABSTRACT
BACKGROUND:
During the last few years it has been shown in several laboratories that Celecoxib (Cx), a non-steroidal anti-inflammatory agent (NSAID) normally used for pain and arthritis, mediates antitumor and antiangiogenic effects. However, the effects of this drug on a tumor cell line resistant to chemotherapeutical drugs used in cancer have not been described. Herein we evaluate the angiogenic and antitumor effects of Cx in the development of a drug-resistant mammary adenocarcinoma tumor (TA3-MTXR).RESULTS:
Cx reduces angiogenesis in the chick embryonic chorioallantoic membrane assay (CAM), inhibits the growth and microvascular density of the murine TA3-MTXR tumor, reduces microvascular density of tumor metastases, promotes apoptosis and reduces vascular endothelial growth factor (VEGF) production and cell proliferation in the tumor.CONCLUSION:
The antiangiogenic and antitumor Cx effects correlate with its activity on other tumor cell lines, suggesting that Prostaglandins (PGs) and VEGF production are involved. These results open the possibility of using Celecoxib combined with other experimental therapies, ideally aiming to get synergic effects.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Pyrazoles
/
Sulfonamides
/
Tumeurs du sein
/
Anti-inflammatoires non stéroïdiens
/
Apoptose
/
Résistance aux médicaments antinéoplasiques
/
Tumeurs du poumon
/
Néovascularisation pathologique
Limites du sujet:
Animaux
langue:
Anglais
Texte intégral:
Biol. Res
Thème du journal:
Biologie
Année:
2014
Type:
Article
Pays d'affiliation:
Chili
Institution/Pays d'affiliation:
Universidad de Chile/CL
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS